Velum Inc.
Cambridge, MA
- UEI
- Y5DJXLQZL6F8
- CAGE
- 7UM93
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 254 Upland Rd, Cambridge, MA 02140, USA
- Website
- velumtherapeutics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Velum Inc.
Velum Inc. is a corporate entity registered in SAM.gov since 2017, located in Cambridge, Massachusetts, that appears to specialize in advanced peptide therapeutic research and development. The company focuses on innovative pharmaceutical research, particularly in metabolic disease, obesity treatment, and neurological protection through peptide-based drug development. Its primary operational approach involves designing novel peptide molecules that can address complex medical challenges, with a particular emphasis on creating stable, long-acting therapeutic compounds that can potentially treat conditions like type 2 diabetes, obesity, and neurodegenerative disorders.
The federal grant awards demonstrate Velum Inc.'s concentrated research efforts across multiple interconnected therapeutic domains, all centered on peptide-based interventions. The company has received multiple project grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of General Medical Sciences, totaling approximately $315,342. Its research projects have included developing a novel weight loss drug centered on peptide YY (PYY) that synergizes with other hormonal functions, creating protease-stable N-terminally modified therapeutic peptides to extend peptide half-life, and designing triagonist peptide therapeutics for neuroprotection. The research aims to address significant medical challenges such as obesity, type 2 diabetes, metabolic syndrome, and neurological conditions like traumatic brain injury, focusing on innovative peptide modification techniques that can improve drug stability, efficacy, and receptor interactions.
Quick answers
What is Velum Inc.'s UEI?
Velum Inc.'s Unique Entity ID (UEI) in SAM.gov is Y5DJXLQZL6F8.
What is Velum Inc.'s CAGE code?
Velum Inc.'s CAGE code is 7UM93.
Where is Velum Inc. located?
Velum Inc.'s physical address in SAM.gov is 254 Upland Rd, Cambridge, MA 02140, USA.
Is Velum Inc. registered in SAM.gov?
Yes. Velum Inc.'s SAM.gov registration is active through August 10, 2027.
What is Velum Inc.'s most recent federal award?
Velum Inc.'s most recent federal grant award is Peptide YY triagonist weight loss drugs - project summary the growing global epidemic of obesity poses a major public… (R41DK145340), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 1, 2025.
On GovTribe
See Velum Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors